Biologic Activities of the pertusis toxin B-pentamer
Biologic Activities of the pertusis toxin B-pentamer
批准号:
7924036
负责人:
WILLIAM E MILLER
金额:
$35.33万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1986
资助国家:
美国
项目状态:
已结题
起止时间:
1986-07-01 至 2012-08-31
关键词:
AffectApoptosisArrestinsAttenuatedBindingBinding ProteinsBinding SitesBiologicalBiological ModelsBordetella pertussisCD4/CD8 ratio procedureCell DeathCell ProliferationCell Surface ReceptorsCell surfaceCellsChemokine (C-C Motif) Receptor 5ChemotaxisComplement Factor BComplexCytoplasmDataDevelopmentDiseaseElementsEventGTP-Binding ProteinsHIV InfectionsHealthcareHumanImmune responseImmune systemIncidenceIndividualLeukocyte TraffickingLeukocytesLinkLymphocyteMammalian CellMediatingMusMutationPertussisPertussis ToxinPertussis VaccinePhenotypePhosphorylationPublishingReceptor SignalingRegulationReportingResourcesRoleSelectinsSignal PathwaySignal TransductionSignaling ProteinSplenocyteStudy SectionT cell responseT-Cell ActivationT-LymphocyteTherapeuticToxic effectToxinUnited StatesVaccinatedVaccine AntigenVaccinesVirulence FactorsWorkZAP-70 Geneattenuationbasebeta-Chemokineschemokine receptordesensitizationimprovedin vivoinsightmigrationmutantpertussis toxin receptorreceptorresponse
中文摘要
描述(由申请人提供):百日咳毒素(PTX)是一种复合AB 5毒素,由酶活性“A”亚基(S1)和结合性“B”寡聚体(PTX-B)组成,后者由5个亚基S2、S3、S4和S5组成,发现比例为1:1:2:1。AB毒素的B部分将A亚单位转运至靶细胞的细胞质,并且不被认为参与毒性。然而,PTX-B已被证明除了其促进S1进入细胞质的作用之外还具有活性。PTX-B诱导一系列细胞反应,包括立即细胞死亡、细胞凋亡、细胞聚集甚至细胞增殖。在本提案中,我们将鉴定PTX-B的受体,我们将使用T细胞作为模型系统来表征受PTX-B结合影响的信号传导途径,并且我们将表征其对免疫系统其他细胞的毒性。
具体目标1。PTX-B结合元件的表征。PTX-B已被证明与细胞上的多种受体结合。我们将确定必要的PTX-B结合区域作为鉴定潜在细胞表面受体的前奏。
具体目标2。确定PTX-B减弱趋化因子受体信号传导和趋化性的机制。PTX-B影响趋化因子受体活性的机制在很大程度上仍然未知。我们将扩展我们对T细胞中PTX-B信号传导机制的研究,以确定PTX-B是否通过使用趋化因子受体CCR 5作为模型系统促进趋化因子受体脱敏来阻断淋巴细胞迁移。
具体目标3。表征原代细胞对完整百日咳毒素和PTX-B的应答能力。已发表的报告表明,小鼠和人类对PTX-B的反应是不同的。我们建议的特点,短期和长期的反应,人类和小鼠白细胞都完整的百日咳毒素和PTX-B。
百日咳毒素是百日咳杆菌的主要毒力因子,百日咳杆菌是人类百日咳或百日咳的病原体。百日咳是一种常见的地方性疾病,消耗了大量的卫生保健资源,是美国唯一一种发病率正在上升的疫苗可预防疾病。B。百日咳能够感染先前感染或接种疫苗的个体,这是由于其能够阻碍保护性免疫应答的发展,并且理解百日咳毒素与免疫系统的相互作用对于开发改进的百日咳疫苗和治疗剂是重要的。
英文摘要
DESCRIPTION (provided by applicant): Pertussis toxin (PTX) is a complex AB5 toxin, comprised of the enzymatically active, "A" subunit (S1), and the binding, "B" oligomer (PTX-B), composed of five subunits S2, S3, S4, and S5, found in a 1:1:2:1 ratio. The B portions of AB toxins transport the A subunit to the cytoplasm of target cells, and were not thought to participate in toxicity. However PTX-B has been shown to have activity in addition to its role in facilitating entry of S1 into the cytoplasm. PTX-B induces a spectrum of cellular responses, including immediate cell death, development of apoptosis, cellular clustering, and even cellular proliferation. In this proposal we will identify the receptors for PTX-B, we will characterize the signaling pathways that are affected by binding of PTX-B using T cells as a model system, and we will characterize its toxicity to other cells of the immune system.
Specific Aim 1. Characterization of the PTX-B binding elements. PTX-B has been shown to bind to multiple receptors on cells. We will identify the essential PTX-B binding regions as a prelude to the identification of potential cell surface receptors.
Specific Aim 2. Determine the mechanism by which PTX-B attenuates chemokine receptor signaling and chemotaxis. The mechanism by which PTX-B affects chemokine receptor activity remains largely unknown. We will extend our studies on the mechanism(s) of PTX-B signaling in T-cells to determine if PTX-B blocks lymphocyte migration by promoting chemokine receptor desensitization using the chemokine receptor CCR5 as a model system.
Specific Aim 3. Characterize the ability of primary cells to respond to intact pertussis toxin and PTX-B. Published reports suggest that the responses to PTX-B are different between mice and humans. We propose to characterize the short term and long-term responses of human and murine leukocytes both intact pertussis toxin and PTX-B.
Pertussis toxin is the major virulence factor of Bordetella pertussis, the causative agent of human whooping cough or pertussis. Whooping cough is common, endemic, and consumes a significant amount of health care resources, and is the only vaccine-preventable disease that is increasing in incidence in the United States. B. pertussis is able to infect previously infected or vaccinated individuals due to its ability to impede the development of a protective immune response, and understanding the interaction of pertussis toxin with the immune system is important for developing improved pertussis vaccines and therapeutics.
期刊论文(31)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Discovery, purification, and characterization of a temperate transducing bacteriophage for Bordetella avium.
鸟博德特氏菌温带转导噬菌体的发现、纯化和表征。
DOI:
10.1128/jb.182.21.6130-6136.2000
发表时间:
2000
期刊:
Journal of bacteriology
影响因子:
3.2
作者:
[Shelton,CB, Crosslin,DR, Casey,JL, Ng,S, Temple,LM, Orndorff,PE]
通讯作者:
Orndorff,PE
Use of the promoter fusion transposon Tn5 lac to identify mutations in Bordetella pertussis vir-regulated genes.
使用启动子融合转座子 Tn5 lac 鉴定百日咳博德特氏菌 vir 调节基因的突变。
DOI:
10.1128/iai.57.9.2674-2682.1989
发表时间:
1989
期刊:
Infection and immunity
影响因子:
3.1
作者:
[Weiss,AA, Melton,AR, Walker,KE, Andraos-Selim,C, Meidl,JJ]
通讯作者:
Meidl,JJ
Identification and characterization of the carbohydrate ligands recognized by pertussis toxin via a glycan microarray and surface plasmon resonance.
通过聚糖微阵列和表面等离子共振对百日咳毒素识别的碳水化合物配体进行鉴定和表征。
DOI:
10.1021/bi100474z
发表时间:
2010
期刊:
Biochemistry
影响因子:
2.9
作者:
[Millen,ScottH, Lewallen,DanielM, Herr,AndrewB, Iyer,SuriS, Weiss,AlisonA]
通讯作者:
Weiss,AlisonA
Antibacterial agents and release of periplasmic pertussis toxin from Bordetella pertussis.
抗菌剂和百日咳博德特氏菌周质百日咳毒素的释放。
DOI:
10.1128/aac.44.5.1383-1386.2000
发表时间:
2000
期刊:
Antimicrobial agents and chemotherapy
影响因子:
4.9
作者:
[Craig-Mylius,KA, Weiss,AA]
通讯作者:
Weiss,AA
DOI:
10.4049/jimmunol.0803114
发表时间:
2009-05-01
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Schneider OD, Weiss AA, Miller WE]
通讯作者:
Miller WE
共 14 条
Investigation of the role of HDAC activity in regulation of HCMV replication in the salivary epithelium
-
批准号:10739852
-
项目类别:
-
资助金额:$24.3万
-
财政年份:2023
-
负责人:WILLIAM E MILLER
-
依托单位:
Mechanisms of vGPCR mediated Cytomegalovirus Growth in the Salivary Gland
-
批准号:10180884
-
项目类别:
-
资助金额:$40.11万
-
财政年份:2018
-
负责人:WILLIAM E MILLER
-
依托单位:
Development of salisphere-derived systems for the study of cytomegalovirus vGPCR directed viral growth in the salivary gland
-
批准号:9317077
-
项目类别:
-
资助金额:$24.53万
-
财政年份:2017
-
负责人:WILLIAM E MILLER
-
依托单位:
Mechanisms of vGPCR mediated Cytomegalovirus Growth in the Salivary Gland
-
批准号:9332531
-
项目类别:
-
资助金额:$39.5万
-
财政年份:2016
-
负责人:WILLIAM E MILLER
-
依托单位:
Role of Cytomegalovirus GPCRs in Pathogenesis in Vivo
-
批准号:8514752
-
项目类别:
-
资助金额:$30.64万
-
财政年份:2012
-
负责人:WILLIAM E MILLER
-
依托单位:
HCMV US28 Signal Transduction by Betaarrestin proteins
-
批准号:7068459
-
项目类别:
-
资助金额:$26.23万
-
财政年份:2005
-
负责人:WILLIAM E MILLER
-
依托单位:
HCMV US28 Signal Transduction by Betaarrestin proteins
-
批准号:7371077
-
项目类别:
-
资助金额:$24.99万
-
财政年份:2005
-
负责人:WILLIAM E MILLER
-
依托单位:
HCMV US28 Signal Transduction by Betaarrestin proteins
-
批准号:6987737
-
项目类别:
-
资助金额:$22.83万
-
财政年份:2005
-
负责人:WILLIAM E MILLER
-
依托单位:
HCMV US28 Signal Transduction by Betaarrestin proteins
-
批准号:7188515
-
项目类别:
-
资助金额:$25.47万
-
财政年份:2005
-
负责人:WILLIAM E MILLER
-
依托单位:
HCMV US28 Signal Transduction by Betaarrestin proteins
-
批准号:7582343
-
项目类别:
-
资助金额:$24.99万
-
财政年份:2005
-
负责人:WILLIAM E MILLER
-
依托单位:
Environmental Carcinogenesis and Mutagenesis
-
批准号:10189584
-
项目类别:
-
资助金额:$54.87万
-
财政年份:1988
-
负责人:WILLIAM E MILLER
-
依托单位:
Environmental Carcinogenesis and Mutagenesis
-
批准号:10630963
-
项目类别:
-
资助金额:$60.27万
-
财政年份:1988
-
负责人:WILLIAM E MILLER
-
依托单位:
Environmental Carcinogenesis and Mutagenesis
-
批准号:10415926
-
项目类别:
-
资助金额:$71.14万
-
财政年份:1988
-
负责人:WILLIAM E MILLER
-
依托单位:
Biologic Activities of the pertusis toxin B-pentamer
-
批准号:7371627
-
项目类别:
-
资助金额:$35.33万
-
财政年份:1986
-
负责人:WILLIAM E MILLER
-
依托单位:
Biologic Activities of the pertusis toxin B-pentamer
-
批准号:7662109
-
项目类别:
-
资助金额:$35.1万
-
财政年份:1986
-
负责人:WILLIAM E MILLER
-
依托单位:
PHARMACOKINETICS OF INTRAPLEURAL AND INTRAPERITONEAL CISPLATIN
-
批准号:4703668
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WILLIAM E MILLER
-
依托单位:
PHARMACOKINETICS OF INTRAPLEURAL AND INTRAPERITONEAL CISPLATIN
-
批准号:3976123
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WILLIAM E MILLER
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: